Back to all studies
CompletedISRCTN68824876

Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia

This study is completed. It focuses on schizophrenia and currently lists study information in the United Kingdom.

SchizophreniaDrugFrom 18 Years to 65 Years
Need help deciding?

Ask HopeStage to help me review this study

This study may no longer be open, but we can help you understand it and find similar studies.

Loading the security check...
Study ID: ISRCTN68824876. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether a study medication may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United Kingdom.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

The public record does not provide enough detail to summarize the visit format or participation steps clearly. Check the official source for the exact eligibility criteria, locations, contact details, and current recruiting status before taking any next step.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateSeptember 2011
Recruitment status
Completed
Estimated enrollment
Not clearly listed
Sponsor
Imperial College London
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
ISRCTN68824876
Official title
Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia
Official source
Official registry link

Ask HopeStage to help me review this study

This study may no longer be open, but we can help you understand it and find similar studies.

Loading the security check...
Study ID: ISRCTN68824876. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires a lighter follow-up, often with questionnaires or check-ins.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring behavioral or lifestyle intervention for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Imperial College London, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me